Amarin Corp Plc (AMRN)

[HDGabor]

K-

In total CV events in women exceed men but that's because women live longer and there are more of them over 75.

First of all check the meaning of "age-adjusted" and read the link again (with this knowledge).

Wife worked in ER and confirms false positives for Angina were more common in women then men .

So I think the data from JELIS is somewhat skewed in relationship to what to expect in R-It .

Do you realize that it means that JELIS was over (and not underreported)? Maybe the "real" rate was lower ...

I also think the placebo rate for R-It will be closer to 5.2 largely because of more aggressive intervention ( high dose use of high intensity statins etc

Yes, the statin is more intensive than in JELIS But it is irrelevent, since if JELIS could give any guidance (as I think) it gives about R-IT active / V arm and not about the placebo. Crestor was approved in 2004, R-IT design was finalized in 2011. What is the new information (was available after R-IT design) that could affect the placebo estimation? Please notre: new means the trend / relation / etc wasn't known before final R-IT design and data about recent years (was available for previous years) won't be counted as new. e.g. CVD rate between 2011-2014 isn't a new information, since the trend was the same between 2000-2010.

Best,
G